Navigation Links
NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy
Date:12/4/2009

BOSTON and HOUSTON, Dec. 4 /PRNewswire-FirstCall/ -- AES Annual Meeting, Booth #901-- Cyberonics, Inc. (Nasdaq: CYBX) announced today that Vagus Nerve Stimulation (VNS) Therapy, the only FDA-approved implantable medical device for the treatment of refractory epilepsy, will be featured in 14 presentations at the American Epilepsy Society's (AES) Annual Meeting, taking place December 4-8 at the Hynes Convention Center in Boston, Massachusetts.

Robert Elliott, M.D., chief resident of Neurosurgery at NYU Langone Medical Center, will present results of the study entitled, "Vagus Nerve Stimulation for Refractory Epilepsy: Single Surgeon Experience of over 700 Consecutive Operations," on Monday, December 7 at 4:00 p.m. The study was designed to analyze the efficacy and safety of VNS Therapy in a large series of consecutive adults and children with medically refractory epilepsy.

Dr. Elliott and his colleagues at NYU Langone Medical Center conducted a retrospective review of 507 consecutive patients with refractory epilepsy who underwent a total of 720 VNS-related procedures between November 1997 and April 2008. Outcome analysis was performed on 436 patients who underwent primary implantation at the center and had at least one year of follow-up since implantation. Duration of VNS Therapy ranged from one week to 11.35 years.

The results showed a more than 50 percent reduction in seizure frequency occurred in 64.6 percent of patients and 42.1 percent of patients experienced more than a 70 percent reduction in seizure frequency. Patients who had failed intracranial epilepsy procedures prior to VNS Therapy had similar outcomes to those who did not have prior surgery. There were no significant differences in efficacy between adults and children.

"Our study reviewing more than 700 consecutive VNS Therapy procedures further confirms the safety and efficacy of VNS Therapy for medically refractory epilepsy," said Dr. Elliot. "Patients evaluated in this study varied in age, seizure frequency and treatment histories, and the vast majority of patients saw significant improvements in their seizure control. VNS Therapy continues to be an effective way to treat medically refractory epilepsy while possibly improving the quality-of-life for patients."

"Dr. Elliott's study reaffirms the safety, efficacy and quality-of-life benefits of VNS Therapy," said Dan Moore, president and CEO of Cyberonics. "Worldwide, more than 50,000 patients with epilepsy have received VNS Therapy, and a significant majority of these patients are consistently opting to continue treatment, which is evidenced by an initial reimplant rate that exceeds 70 percent. These findings further establish VNS Therapy as the best option for patients with medically refractory epilepsy who are not candidates for resective surgery or who have failed resective surgery."

About Cyberonics, Inc. and VNS Therapy(® )

Cyberonics, Inc. (Nasdaq: CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the VNS Therapy System, which is FDA-approved for the treatments of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics, Inc. and VNS Therapy is available at http://www.cyberonics.com and www.vnstherapy.com.


Contact:
Helen Shik or Amanda Lazaro Connolly
Schwartz Communications
781-684-0770
cyberonicsepilepsy@schwartz-pr.com

SOURCE Cyberonics, Inc.


'/>"/>
SOURCE Cyberonics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Kenneth G. Langone, Home Depot Co-Founder, Chairman of the NYU Langone Medical Center, to Lead 65th Annual Columbus Day Parade as Grand Marshal
2. NYU Langone Medical Centers tip sheet to the 45th Annual Meeting of ASCO
3. NYU Langone Medical Center study shows that cochlear implant surgery is safe for the elderly
4. SIRIUS Satellite Radio & NYU Langone Medical Center Launch Doctor Radio Channel
5. NYU Langone Medical Centers tip sheet to the 44th annual meeting of ASCO
6. North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program
7. IntelliSoft Group Focuses on Protecting Customer Investment in Medical Credentialing Systems -- Budget Constraints and Forced Upgrades in Medical Credentialing Automation
8. Florida Medical Association Marks Record Membership Growth
9. Topping Out Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro
10. Chiltern Names Dr. Sharon Moore as Executive VP, Global Quality & Medical Affairs
11. Personality predicts success in medical school, says new study by U of Minnesota professor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 2017 , ... An in-depth computational analysis of genetic variants implicated in both ... genes that may explain why susceptibility to one of the disorders could place individuals ... today in the journal npj Schizophrenia. , “There is a wealth of genomic ...
(Date:2/24/2017)... Texas (PRWEB) , ... February 24, 2017 , ... ... to The Medical Center at Craig Ranch building at 8080 State Highway 121, Suite ... Medical District with easy access to Highway 121. , As the practice has grown, ...
(Date:2/24/2017)... ... , ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 ... image mannequin art competition. Selected from 15 submissions from around the nation, the top ... 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. , This year, ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle ... hosted their Military Wedding Giveaway, with the winning couple announced on Feb. 14, ... services generously donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... clinician-based audience, will be participating in Rare Disease Day events, hosted by the ... addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will be ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Februar 2017 LG Innotek hat heute die ... Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der Konkurrenz. ... zwischen 200 und 280 nm und eignet sich damit für ... ihre DNA zerstört. Das Produkt von LG Innotek erzeugt ... ...
(Date:2/23/2017)... Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die Guian ... Provinz Guizhou, 2017 mit dem Angebot von Anreize schaffenden Strategien ... einer eingebetteten Hightech-Schlüsselindustrie. Foto - http://mma.prnewswire.com/media/471342/First_CRH__CHina_Railway_High_Speed__Train_Enters_Guian.jpg ... ... ...
(Date:2/23/2017)... New York , February 23, 2017 ... implications arising from increasing caseload for varicose veins in ... across the globe are prompting the adoption of endovenous ... study on global endovenous laser therapy market, ... towards aftereffects of lifestyle choices and consequences of obesity ...
Breaking Medicine Technology: